TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ADZENYS XR-ODT

AMPHETAMINE
Metabolic Approved 2016-01-27
1
Indication
--
Phase 3 Trials
10
Years on Market

Details

Status
Prescription
First Approved
2016-01-27
Routes
ORAL
Dosage Forms
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE

Companies

Active Ingredient: AMPHETAMINE

ADZENYS XR-ODT Approval History

Loading approval history...

What ADZENYS XR-ODT Treats

1 indications

ADZENYS XR-ODT is approved for 1 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Attention Deficit Hyperactivity Disorder
Source: FDA Label

ADZENYS XR-ODT Boxed Warning

ABUSE, MISUSE AND ADDICTION ADZENYS XR-ODT has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ADZENYS XR-ODT, can result in overdose and death [see Overdosage (10)] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing ADZENYS XR-ODT, assess each patient’s risk for abuse, misuse, and addiction...

Drugs Similar to ADZENYS XR-ODT

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADDERALL XR 10
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADDERALL XR 15
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADDERALL XR 20
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADDERALL XR 25
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADDERALL XR 30
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADDERALL XR 5
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
AMPHETAMINE SULFATE
AMPHETAMINE SULFATE
1 shared
PRINSTON INC
Shared indications:
Attention Deficit Hyperactivity Disorder
APTENSIO XR
METHYLPHENIDATE HYDROCHLORIDE
1 shared
RHODES PHARMS
Shared indications:
Attention Deficit Hyperactivity Disorder
ARYNTA
LISDEXAMFETAMINE DIMESYLATE
1 shared
AZURITY
Shared indications:
Attention Deficit Hyperactivity Disorder
AZSTARYS
DEXMETHYLPHENIDATE HYDROCHLORIDE
1 shared
COMMAVE THERAP
Shared indications:
Attention Deficit Hyperactivity Disorder
CONCERTA
METHYLPHENIDATE HYDROCHLORIDE
1 shared
Johnson & Johnson
Shared indications:
Attention Deficit Hyperactivity Disorder
COTEMPLA XR-ODT
METHYLPHENIDATE
1 shared
NEOS THERAPS INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DAYTRANA
METHYLPHENIDATE
1 shared
NOVEN PHARMS INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DEXEDRINE SPANSULE
DEXTROAMPHETAMINE SULFATE
1 shared
IMPAX LABS INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DEXTROAMPHETAMINE SULFATE
DEXTROAMPHETAMINE SULFATE
1 shared
SPECGX LLC
Shared indications:
Attention Deficit Hyperactivity Disorder
DYANAVEL XR
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DYANAVEL XR 10
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DYANAVEL XR 15
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DYANAVEL XR 20
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DYANAVEL XR 5
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Attention Deficit Hyperactivity Disorder
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ADZENYS XR-ODT FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

ADZENYS XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [see Clinical Studies ]. Limitations of Use The use of ADZENYS XR-ODT is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g. weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions . Use in Specific Populations ] . ADZENYS XR-ODT is a central nervous system (CNS) stimulant indicated for th...

⚠️ BOXED WARNING

WARNING: ABUSE, MISUSE AND ADDICTION ADZENYS XR-ODT has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ADZENYS XR-ODT, can result in overdose and death [see Overdosage (10)] , an...

ADZENYS XR-ODT Patents & Exclusivity

Latest Patent: Jun 2032

Patents (180 active)

US8709491 Expires Jun 28, 2032
US9017731 Expires Jun 28, 2032
US9839619 Expires Jun 28, 2032
US9265737 Expires Jun 28, 2032
US8840924 Expires Apr 9, 2026
+ 170 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.